TY - JOUR
T1 - Bone Marrow Mesenchymal Stromal Cells Drive Protective M2 Microglia Polarization After Brain Trauma
AU - Zanier, Elisa R.
AU - Pischiutta, Francesca
AU - Riganti, Loredana
AU - Marchesi, Federica
AU - Turola, Elena
AU - Fumagalli, Stefano
AU - Perego, Carlo
AU - Parotto, Emanuela
AU - Vinci, Paola
AU - Veglianese, Pietro
AU - D'Amico, Giovanna
AU - Verderio, Claudia
AU - De Simoni, Maria Grazia
PY - 2014
Y1 - 2014
N2 - Microglia/macrophages (M) are major contributors to postinjury inflammation, but they may also promote brain repair in response to specific environmental signals that drive classic (M1) or alternative (M2) polarization. We investigated the activation and functional changes of M in mice with traumatic brain injuries and receiving intracerebroventricular human bone marrow mesenchymal stromal cells (MSCs) or saline infusion. MSCs upregulated Ym1 and Arginase-1 mRNA (p <0.001), two M2 markers of protective M polarization, at 3 and 7 d postinjury, and increased the number of Ym1+ cells at 7 d postinjury (p <0.05). MSCs reduced the presence of the lysosomal activity marker CD68 on the membrane surface of CD11b-positive M (p <0.05), indicating reduced phagocytosis. MSC-mediated induction of the M2 phenotype in M was associated with early and persistent recovery of neurological functions evaluated up to 35 days postinjury (p <0.01) and reparative changes of the lesioned microenvironment. In vitro, MSCs directly counteracted the proinflammatory response of primary murine microglia stimulated by tumor necrosis factor-α + interleukin 17 or by tumor necrosis factor-α + interferon-γ and induced M2 proregenerative traits, as indicated by the downregulation of inducible nitric oxide synthase and upregulation of Ym1 and CD206 mRNA (p <0.01). In conclusion, we found evidence that MSCs can drive the M transcriptional environment and induce the acquisition of an early, persistent M2-beneficial phenotype both in vivo and in vitro. Increased Ym1 expression together with reduced in vivo phagocytosis suggests M selection by MSCs towards the M2a subpopulation, which is involved in growth stimulation and tissue repair.
AB - Microglia/macrophages (M) are major contributors to postinjury inflammation, but they may also promote brain repair in response to specific environmental signals that drive classic (M1) or alternative (M2) polarization. We investigated the activation and functional changes of M in mice with traumatic brain injuries and receiving intracerebroventricular human bone marrow mesenchymal stromal cells (MSCs) or saline infusion. MSCs upregulated Ym1 and Arginase-1 mRNA (p <0.001), two M2 markers of protective M polarization, at 3 and 7 d postinjury, and increased the number of Ym1+ cells at 7 d postinjury (p <0.05). MSCs reduced the presence of the lysosomal activity marker CD68 on the membrane surface of CD11b-positive M (p <0.05), indicating reduced phagocytosis. MSC-mediated induction of the M2 phenotype in M was associated with early and persistent recovery of neurological functions evaluated up to 35 days postinjury (p <0.01) and reparative changes of the lesioned microenvironment. In vitro, MSCs directly counteracted the proinflammatory response of primary murine microglia stimulated by tumor necrosis factor-α + interleukin 17 or by tumor necrosis factor-α + interferon-γ and induced M2 proregenerative traits, as indicated by the downregulation of inducible nitric oxide synthase and upregulation of Ym1 and CD206 mRNA (p <0.01). In conclusion, we found evidence that MSCs can drive the M transcriptional environment and induce the acquisition of an early, persistent M2-beneficial phenotype both in vivo and in vitro. Increased Ym1 expression together with reduced in vivo phagocytosis suggests M selection by MSCs towards the M2a subpopulation, which is involved in growth stimulation and tissue repair.
KW - Immunomodulation
KW - Macrophages
KW - Mesenchymal stromal cells
KW - Microglia
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=84905568615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905568615&partnerID=8YFLogxK
U2 - 10.1007/s13311-014-0277-y
DO - 10.1007/s13311-014-0277-y
M3 - Article
C2 - 24965140
AN - SCOPUS:84905568615
VL - 11
SP - 679
EP - 695
JO - Neurotherapeutics
JF - Neurotherapeutics
SN - 1933-7213
IS - 3
ER -